Cardiogen (AEDR) record · updated 20h ago

Healing & recoveryMetabolic & appetiteGrade A · human clinicalResearch use only

All 4 studies Jump to the evidence Compare

What is Cardiogen (AEDR) used for?

Cardiogen (AEDR) is a short synthetic peptide bioregulator researched primarily for cardiovascular tissue support, vascular function, and age-related cardiac decline in preclinical models.

Primarily researched for · Healing & recovery

Development stage

where Cardiogen (AEDR) sits between preclinical work and regulatory approval

1Cleared
Preclinical
Animal / in-vitro work
2Cleared
Phase 1
Safety in humans
3Cleared
Phase 2
Efficacy signal
4Current
Phase 3
Confirmatory trials
5Not reached
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 4 registered trials. It describes the research record, not a recommendation.

Identity

NameCardiogen (AEDR)

Chain length—

Molecular weight161.2 Da

FormulaC7H15NO3

Structure typeSmall molecule

ClassLongevity

Research levelModerate Research

Discovered byCurated master list · 2026

Mass and formula from PubChem CID 10917. No verified residue count for this compound.

Pharmacology

Mechanism—

Route—

Half-life—

Time to peak—

Duration—

Extraction confidence—

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 5, 2026. How this works →

Research stats

Total studies4

Human / animal / cellular2 / 0 / 0

Highest trial phasePhase 3

Years covered2026

Latest study21d ago

Publication history

20262026

Research funding

—no NIH grants found

Safety signals

FAERS reportsnone recorded

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

ChEMBL ClinicalTrials.gov DrugBank Google Scholar PubChem PubMed · 4 Semantic Scholar UniProt

Study register

4 rowsOpen in the library →

SortDate added ↓Publication year Evidence type Summary depth

Study	Type	Year	Summary depth
SPARC: a structural pathogenicity algorithm for risk classification of hERG variants. Finding260 variants identified as high risk of pathogenicity with SPS ≥3.25.	review	2026	Full text read0.70
Echocardiographic risk stratification in heart failure with post-capillary pulmonary hypertension: prognostic value of LAVI and TAPSE/PASP. FindingHR 1.97, 95% CI 1.41-2.75; P < 0.0001	Human	2026	Full text read0.80
Expert-Designed Fact Sheets and AI-Based Analysis of Patient Symptoms to Combat Diagnostic Delays in Inherited Metabolic Diseases. FindingNot reported in abstract.	review	2026	Full text read0.70
Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial. FindingVutrisiran reduced the primary composite endpoint in women (HR 0.59, 95% CI 0.26-1.30) and men (HR 0.71, 95% CI 0.54-0.94; p-interaction = 0.66).	Human	2026	Full text read0.85

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Cardiogen (AEDR) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Cardiogen (AEDR) is discussed should be drawn from it.